WILLOW BIOSCIENCES INC - CANSF STOCK NEWS

Willow Biosciences (CANSF) provided updates on its operations as of Sept. 21, 2021. The company completed its first commercial fermentation run of CBG in March 2021, increasing production titer by over 400%. CBG samples were delivered to Cellular Goods PLC in July 2021. Willow has also developed a process for producing cannabigerolic acid (CBGA), now available for customer evaluation. However, the company faces a patent infringement claim related to CsPT1, which it states is without merit, as it does not use this enzyme in its processes.

Willow Biosciences has entered a multi-year supply agreement with Cellular Goods to provide ultra-pure, biosynthetically produced cannabigerol (CBG) for use in skincare products set to launch in autumn 2021. The first shipment is scheduled for July 2021. Willow's CBG has demonstrated safety and beneficial properties on human skin, making it a suitable ingredient for cosmetics in the evolving UK market, where CBG is now approved for use. This agreement marks Willow's first commercial supply of CBG, enhancing its position in the growing cannabinoid sector.

Willow Biosciences Inc. (CANSF) announced participation in a panel at SynBioBeta's conference on May 26, 2021, focusing on synthetic biology in biopharma. The event features industry leaders discussing advancements in bioproduction. Willow, specializing in sustainable cannabinoid production through yeast-based biosynthesis, aims to showcase its innovative approaches. This participation supports Willow's ongoing efforts in the biotech sector, particularly in creating high-purity, plant-derived ingredients.

Willow Biosciences, a Canadian biotechnology firm, has been added to the Cannabis ETF (THCX) on NYSE Arca as of May 18, 2021. This milestone, timed with the company's shift to commercialization of cannabigerol (CBG), aims to attract a broader investor base interested in the rapidly growing cannabinoid market. As the only public entity focused on biosynthetically producing cannabinoids, Willow's innovative manufacturing process promises ultra-pure products with a low environmental impact. The inclusion in THCX aligns with its targeted approach in the expanding cannabis sector.

Willow Biosciences Inc. (OTCQX: CANSF) announced positive results from a series of studies with Signum Biosciences, showing the safety and anti-inflammatory benefits of their cannabigerol (CBG). Willow CBG demonstrated no irritation on skin and eyes, and displays potent antioxidant and anti-inflammatory properties, surpassing that of CBD in certain tests. These findings pave the way for commercialization in skincare, with the full data set to be shared at the Society for Investigative Dermatology meeting on May 3, 2021. Willow's CBG could become a key player in the cannabinoid market.

Willow Biosciences Inc. (OTCQX: CANSF) has successfully completed its first commercial scale fermentation run of cannabigerol (CBG). The company is pleased with the yield and quality achieved. With over two years as a public entity, Willow has built a strong R&D team and partnered with Albany Molecular Research for development. Production is set to meet growing demand for ultra-pure CBG, with agreements being finalized with multiple clients. Additionally, preliminary safety data from Signum Biosciences indicates CBG's potential as a cosmetic ingredient, showcasing its antioxidant and anti-inflammatory properties.

Willow Biosciences Inc. has successfully closed an upsized bought deal offering, raising approximately $28.75 million through the sale of 17,424,800 common shares at $1.65 each. The offering attracted significant participation from cornerstone and institutional investors. Proceeds will be used to expand market access for Willow's cannabinoid portfolio, expedite commercialization, and enhance manufacturing capacity. With the first cannabinoid commercialization expected in Q1 2021, Willow aims to leverage its strong financial position to pursue growth opportunities.

Willow Biosciences Inc. (OTCQX: CANSF) is collaborating with the University of Lethbridge and the University of Calgary to investigate the therapeutic effects of non-psychoactive cannabinoids on intestinal inflammation, abdominal pain, and depression. Funded by Alberta Innovates, the study will utilize four non-plant-derived cannabinoids in preclinical models. The project, led by Dr. Aaron Gruber, aims to explore new treatment options for inflammatory conditions. This partnership allows Willow to leverage its manufacturing technologies with minimal investment while positioning itself as a leader in the emerging cannabinoid market.